Mortality and cancer risk on long-term antiplatelet treatment: What is known and what we still don’t know

Dirk Sibbing; Dániel Aradi

doi:10.1160/TH17-03-0180

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2017; 117(05): 823-825
DOI: 10.1160/TH17-03-0180

Invited Editorial Focus

Schattauer GmbH

Mortality and cancer risk on long-term antiplatelet treatment: What is known and what we still don’t know

Dirk Sibbing

¹Medizinische Klinik und Poliklinik I, Klinikum der Universität, Ludwig Maximilians-Universität München, Germany

²DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany

,

Dániel Aradi

³Department of Cardiology, Heart Center Balatonfüred, Semmelweis University, Budapest, Hungary

⁴Heart and Vascular Center, Semmelweis University, Budapest, Hungary

› Author Affiliations

Abstract

Full Text

References

References
1 Mauri L, Kereiakes DJ, Yeh RW. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166.
2 Collet JP, Silvain J, Barthelemy O. et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014; 384: 1577-1585.
3 Navarese EP, Andreotti F, Schulze V. et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. Br Med J 2015; 350: h1618.
4 Palmerini T, Benedetto U, Bacchi-Reggiani L. et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015; 385: 2371-2382.
5 Elmariah S, Mauri L, Doros G. et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015; 385: 792-798.
6 Lagerqvist B, James SK, Stenestrand U. et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
7 Shuchman M. Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006; 355: 1949-1952.
8 Mauri L, Elmariah S, Yeh RW. et al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016; 37: 378-385.
9 Serebruany VL, Kim MH, Cabrera-Fuentes HA. et al. Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). Thromb Haemost 2017; 117: 934-939.
10 Serebruany VL, Cherepanov V, Cabrera-Fuentes HA. et al. Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. Thromb Haemost 2015; 114: 1104-1112.
11 Floyd JS, Serebruany VL. Prasugrel as a potential cancer promoter: review of the unpublished data. Arch Intern Med 2010; 170: 1078-1080.
12 Leader A, Zelikson-Saporta R, Pereg D. et al. The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence. Am J Med. 2017 Epub ahead of print.
13 Kotronias RA, Kwok CS, Wong CW. et al. Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis. Drug Saf 2017; 40: 229-240.
14 Roe MT, Cyr DD, Eckart D. et al. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J 2016; 37: 412-422.
15 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800.
16 Dulai PS, Singh S, Marquez E. et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. Br Med J 2016; 355: i6188.
17 Sibbing D, Massberg S. Dual antiplatelet treatment after stenting: is longer better?. Lancet 2014; 384: 1553-1555.
18 Vries MJ, van der Meijden PE, Henskens YM. et al. Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. A systematic review. Thromb Haemost 2016; 115: 7-24.
19 Yeh RW, Secemsky EA, Kereiakes DJ. et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. J Am Med Assoc 2016; 315: 1735-1749.
20 Lip GY, Windecker S, Huber K. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155-3179.